Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine

Chinese Journal of Integrative Medicine

Volumn 20, Issue 3, 2014, Pages 179-183

  Chen, Yan Zhi ^a   Feng, Xiao Bing ^a   Li, Zhan Dong ^a   Zheng, Wen Xian ^a   Sun, Hong ^a   Li, Ping Ping ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Chinese medicine; long term overall survival; non small cell lung cancer; prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CHINESE MEDICINE; CLINICAL STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LONG TERM SURVIVAL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PERFORMANCE STATUS SCORE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SMOKING; SURVIVAL RATE; SURVIVAL TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; SMOKING; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84896514831     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-014-1770-6     Document Type: Article

References (15)

1. Parkin DM, Bray F, Ferlay J. Global cancer statistics, 2002. CA Caner J Clin 2005;55:74-108. (Pubitemid 40372904)
2. Govindan R, Page N, Morgensztern D, Read W, Tieney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveilance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544. (Pubitemid 46630948)
3. Sequist LV, Martins RG, Spigel D, Steven MG, Alexander S, Pasia J, et al. First-line gefi tinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449.
4. Frances AS, Rodrigues P, Tudor C, Eng Huat Tan, Vera H, Semitra T, et al. Erlotinib in preciously treated non-smallcell lung cancer. N Engl J Med 2005;353:123-132.
5. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996;32:1135-1141.
6. Ye B, Wang LH, Liu XY. Explaine of the revised versin of lung cancer TNM staging standard by International Association of Lung Cancer. Chin J Med 2008;4:21-23.
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
8. Paesmans M, Sculier JP, Libert G. Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin Oncol 1995;13:1221-1230.
9. Sandler A, Gray R, Perry MC. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
10. Ciuleanu T, Brodowicz T, Zielinki C, Kim JH, Kizakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
11. Lin LP, Xiang XJ, Huang H, Zhao HY, Zhang Y. Analysis of the relationship between the response after the firstline chemotherapy and the survival in the advanced non-small cell lung cancer. Chin J Lung Cancer (Chin) 2008;11:333-337.
12. Wu MN, Wang YY, An TT, Zhao J, Yang L. Analysis of prognostic factors in 541 female patients with advanced non-small cell lung cancer. Chin J Lung Cancer (Chin) 2011;14:245-250.
13. Chen YZ, Li ZD, Gao F, Zhang Y, Li PP. Effects of combined Chinese drugs and chemotherapy in treating advanced nonsmall cell lung cancer. Chin J Integr Med 2009;15:415-419.
14. Chen YZ, Di LJ, Zhang SL, Chen MS. Sun H, Gao F. The randomized, multicenter, controlled clinic trail for treating advanced non-small cell lung cancer with combined traditional Chinese medicine and vinorelbine (Navelbine, NVB) plus cisplatin (DDP) chemotherapy. Chin J Lung Cancer (Chin) 2008;11:441-444. (Pubitemid 351976685)
15. Chen YZ, Li ZD, Zhou N, Sun H, Li PP. Longer overall survival in a patient with advanced non-small cell lung cancer treated with Chinese medicine and chemotherapy. Chin J Integr Med 2012;18:626-628.